Novel plasma telomerase detection method to improve cancer diagnostic assessment

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Hilal, George ^a   Reitzel, Ruth ^b   Hamal, Zainab Al ^b   Chaftari, Anne Marie ^b   Wohoush, Iba Al ^b   Jiang, Ying ^b   Hachem, Ray ^b   Raad, Issam I ^b  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER DIAGNOSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PLASMA TELOMERASE; PREDICTION; PREDICTIVE VALUE; PROCESS DEVELOPMENT; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT RESPONSE; VALIDATION PROCESS; ANIMAL; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; ENZYMOLOGY; PANCREATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; VALIDATION STUDY;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; HUMANS; MICE; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TELOMERASE;

EID: 85018785588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174266     Document Type: Article

References (30)

1. Park ES, Lee J, Kang SY, Lee EJ, Lee MH, Yoon N, et al. A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. Anal Quant Cytopathol Histopathol. 2013 Jun; 35(3):146-51
2. Nassani N, Khayat G, Raad I, Jiang Y, Alaaeddine N, Hilal G. Telomerase as a potential marker for inflammation and cancer detection in bronchial washing: a prospective study. Clin Biochem. 2013 Nov; 46(16-17):1701-4. https://doi.org/10.1016/j.clinbiochem.2013.07.018 PMID: 23899579
3. LoKW, LoYM, Leung SF, Tsang YS, Chan LY, Johnson PJ, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999 Aug; 45(8 Pt 1):1292-4
4. Kopreski MS, BenkoFA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 1999 Aug; 5 (8):1961-5
5. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2000 Oct; 6(10):3823-6
6. Novakovic S, Hocevar M, Zgajnar J, Besic N, Stegel V. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Oncol Rep. 2004 Jan; 11(1):245-52. PMID: 14654933
7. Terrin L, RampazzoE, Pucciarelli S, Agostini M, Bertorelle R, EspositoG, et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res Off J Am Assoc Cancer Res. 2008 Nov 15; 14(22):7444-51
8. DasoF, LledoS, Garcoa-GraneroE, Ripoll R, Marugan M, TormoM, et al. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test tomonitor disease in cancer patients. Lab Investig J Tech Methods Pathol. 2001 May; 81(5):767-9
9. Miura N, Kanamori Y, Takahashi M, SatoR, TsukamotoT, Takahashi S, et al. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep. 2007 Mar; 17(3):541-8. PMID: 17273731
10. Fukushima T, YoshinoA, Katayama Y, Watanabe T, Kusama K, Moro I. Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 2002 Dec 10; 187(1-2):191-8. PMID: 12359368
11. Poremba C, Heine B, DialloR, Heinecke A, Wai D, Schaefer K-L, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 2002 Oct; 198(2):181-9. https://doi.org/10.1002/path.1191 PMID: 12237877
12. Sarcione EJ, Zloty M, DelluomoDS, Mizejewski G, Jacobson H. Detection and measurement of alphafetoprotein in human breast cancer cytosol after treatment with 0.4 M potassium chloride. Cancer Res. 1983 Aug; 43(8):3739-41. PMID: 6190555
13. Taneja P, Maglic D, Kai F, ZhuS, Kendig RD, Fry EA, et al. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol. 2010 Apr 20; 4:15-34. PMID: 20567632
14. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene. 2002 Jan 21; 21(4):643-9. https://doi.org/10.1038/sj.onc.1205070 PMID: 11850791
15. Goldkorn A, Ely B, Tangen CM, Tai Y-C, XuT, Li H, et al. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. https://doi.org/10.1002/ijc.29212 PMID: 25219358
16. Larsen JE, Minna JD. Molecular Biology of Lung Cancer: Clinical Implications. Clin Chest Med. 2011 Dec; 32(4):703-40. https://doi.org/10.1016/j.ccm.2011.08.003 PMID: 22054881
17. Ichikawa Y, Kamiyama M, SekidoH, Ishikawa T, Miura Y, Kamiya N, et al. Telomerase activity and Bcl-2 expression in gallbladders of pancreaticobiliary maljunction patients: a preliminary study. J Hepatobiliary Pancreat Surg. 2004; 11(1):34-9. https://doi.org/10.1007/s00534-003-0860-9 PMID: 15754044
18. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013 Oct 22; 110(43):17426-31. https://doi.org/10.1073/ pnas.1310522110 PMID: 24101484
19. JuM, KaoGD, Steinmetz D, Chandrasekaran S, Keefe SM, GuzzoTJ, et al. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy. Cancer Biol Ther. 2014 Jun 1; 15(6):683-7. https://doi.org/10.4161/cbt.28412 PMID: 24618718
20. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, MichailidouK, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013 Apr; 45(4):371-84e2. https://doi.org/10.1038/ng.2566 PMID: 23535731
21. LuL, Zhang C, ZhuG, Irwin M, Risch H, MenatoG, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res BCR. 2011; 13(3):R56. https://doi.org/10.1186/bcr2893 PMID: 21645396
22. Lee C-M, Hsu C-Y, Eng H-L, Huang W-S, Lu S-N, Changchien C-S, et al. Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. Hepatogastroenterology. 2004 Jun; 51(57):796-800. PMID: 15143919
23. Shimada M, Hasegawa H, Gion T, Utsunomiya T, Shirabe K, Takenaka K, et al. The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol. 2000 Mar; 95(3):748-52. https://doi.org/10. 1111/j.1572-0241.2000.01855.x PMID: 10710069
24. Tao S-F, Zhang C-S, Guo X-L, XuY, Zhang S-S, Song J-R, et al. Anti-tumor effect of 5-aza-2-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells. World J Gastroenterol WJG. 2012 May 21; 18(19):2334-43. https://doi.org/10.3748/wjg.v18.i19.2334 PMID: 22654424
25. Wymenga LF, Wisman GB, Veenstra R, Ruiters MH, Mensink HJ. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur J Clin Invest. 2000 Apr; 30(4):330-5. PMID: 10759882
26. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol. 2006 Apr; 24(2):122-30. https://doi.org/10.1016/j.urolonc.2005.11.002 PMID: 16520276
27. Anderson S, Shera K, Ihle J, Billman L, Goff B, Greer B, et al. Telomerase activation in cervical cancer. Am J Pathol. 1997 Jul; 151(1):25-31. PMID: 9212727
28. Bertorelle R, RampazzoE, Pucciarelli S, Nitti D, De Rossi A. Telomeres, telomerase and colorectal cancer. World J Gastroenterol WJG. 2014 Feb 28; 20(8):1940-50. https://doi.org/10.3748/wjg.v20.i8.1940 PMID: 24616570
29. HuX, WuH, Zhang S, Yuan H, CaoL. Clinical significance of telomerase activity in gastric carcinoma and peritoneal dissemination. J Int Med Res. 2009 Aug; 37(4):1127-38. https://doi.org/10.1177/ 147323000903700417 PMID: 19761695
30. Hess JL, Highsmith WE. Telomerase Detection in Body Fluids. Clin Chem. 2002 Jan 1; 48(1):18-24. PMID: 11751534